We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Fully Automated Analyzer Has Multiplex Capabilities

By LabMedica International staff writers
Posted on 16 Aug 2010
A state of the art analyzer offers complete consolidation of the patient's profile for clinical diagnostics. More...


The new advanced machine uses Biochip Array Technology and is capable of testing for multiple analytes simultaneously from a single sample, providing advanced test compilation, and patient profiling.

The Evidence Evolution analyzer provides limitless capabilities enabling simultaneous testing from a single small volume sample. A complete profile of biomarkers can be analyzed from as little as 7.0 µL of sample and the assay menu is extensive. The Evidence Evolution has the ability to process 2,940 tests per hour.

The analyzer was unveiled by Randox Laboratories Ltd. (Crumlin, UK), at the American Association Clinical Chemistry's Clinical Lab Expo in Anaheim (CA, USA) in July 2010. Multiplex testing allows multiple tests to be carried out from an undivided patient sample reducing the amount of time and labor spent on individual tests. True Random Access allows continuous reagents samples and consumable input and output without interrupting testing and batch samples are processed with instant STAT capabilities. The highly accurate testing is achieved by the use of linear Bio-drive Robotics, which delivers fast and highly precise operations with uncompromised quality. The unrivalled mechanical capabilities ensure continuous flow of results.

The array menus include clinical, immunoassays, molecular diagnostics, toxicology, and drug residue assays. The Evidence Evolution is suitable for clinical laboratories with medium to high throughput. The measurement principle is based on chemiluminescence with a 200-biochip capacity yielding up to 9,800 tests containing up to 20 different panels onboard simultaneously. The system also hosts high quality and highly secure remote access diagnostics, ensuring advanced technical support is never more than a click away.

Related Links:

Randox Laboratories Ltd.
American Association Clinical Chemistry




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.